ArticleSkeletal radiology2026
Magnetic resonance imaging appearance of targeted muscle reinnervation and regenerative peripheral nerve interfaces in oncologic amputees.
Article in Skeletal radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesPatients with extremity sarcomas may require amputation when limb salvage surgery is not possible. Targeted muscle reinnervation (TMR) and regenerative peripheral nerve interface (RPNI) are procedures that can reduce neuroma formation, though neuromas can still occur. This study aims to describe the MRI characteristics of TMR/RPNI, examine changes in neuromas over time, and differentiate these from sarcoma recurrence on MRI.
methodsAll patients at our institution between 2013 and 2024 who underwent upper or lower extremity amputation due to sarcoma, underwent TMR/RPNI, and had follow-up MRI imaging were included. Two radiologists evaluated the incidence and appearance (size, signal characteristics, enhancement pattern, morphology) of neuromas and their evolution. Statistical analysis employed the chi-squared test and McNemar's test.
resultsSixty-two TMRs and 46 RPNIs were performed in 26 patients (7 upper, 19 lower extremity amputations). Seven patients had TMR-only, 7 had RPNI-only, and 12 had both, with an average follow-up of 517 days (range 91-1705 days). MRI identified nodular, T2 hyperintense, enhancing foci averaging 0.8 cm in diameter (range 0.3-2.0 cm) at 44% of nerve surgery sites and in 73% of patients at initial follow-up. These foci, presumed to represent neuromas, decreased over time (p < 0.001) with a significant reduction in nodule size for TMR-only patients (p = 0.007). Two recurrences showed increasing irregular nodule size.
conclusionTMR and RPNI procedures show T2 hyperintense nodules on the first follow-up MRI, which decrease in incidence over time. TMR significantly reduces neuroma size. Increases in nodule size should prompt concern for recurrence.
Indexed as
Identifiers
40764828What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.